US4230724A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating vascularization of the eye with Flurbiprofen
Assignee: Allergan Inc
•
Filing: 1979-07-16
•
Granted: 1980-10-28
•
Expires: 1999-07-16
Abstract
Abstract A method of treating vascularization of the eye as a result of traumatic injury, surgery, such as, corneal transplant, or onset of diabetic retinopathy by topically treating the eye with Flurbiprofen or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 Charles A. Cooper
- 👤 Michael V. W. Bergamini
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 06:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61P; A61P27/00; A61P27/02
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
27 words
A method of treating trauma-induced vascularization of the cornea comprising topically administering to the eye an effective, vascularization-inhibiting amount of Flurbiprofen or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
27 words
A method of treating trauma-induced vascularization of the cornea comprising topically administering to the eye an effective, vascularization-inhibiting amount of Flurbiprofen or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the amount of Flurbiprofen ranges between about 0.005 and about 2%.
Claim 4
Dependent Claim
16 words
The method of claim 1 wherein the amount of Flurbiprofen ranges between about 0.03 and 1%.
Claim 5
Independent Claim
30 words
A method of treating surgically-induced vascularization of the cornea following corneal transplant comprising topically administering to the eye an effective, vascularization-inhibiting amount of Flurbiprofen or a pharmaceutically acceptable salt thereof.
Claim 6
Independent Claim
30 words
A method of treating surgically-induced vascularization of the cornea following corneal transplant comprising topically administering to the eye an effective, vascularization-inhibiting amount of Flurbiprofen or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
17 words
The method of claim 4 wherein the amount of Flurbiprofen ranges between about 0.005 and about 2%.
Claim 8
Dependent Claim
16 words
The method of claim 4 wherein the amount of Flurbiprofen ranges between about 0.03 and 1%.
Claim 9
Independent Claim
27 words
A method of treating diabetic retinopathy in humans comprising topically administering to the eye an effective, diabetic retinopathy-inhibiting amount of Flurbiprofen or a pharamaceutically acceptable salt thereof.
Claim 10
Independent Claim
27 words
A method of treating diabetic retinopathy in humans comprising topically administering to the eye an effective, diabetic retinopathy-inhibiting amount of Flurbiprofen or a pharamaceutically acceptable salt thereof.
Claim 11
Dependent Claim
17 words
The method of claim 7 wherein the amount of Flurbiprofen ranges between about 0.005 and about 2%.
Claim 12
Dependent Claim
16 words
The method of claim 7 wherein the amount of Flurbiprofen ranges between about 0.03 and 1%.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-10-28 | 1984-04-28 | 1984-10-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-10-28 | 1988-04-28 | 1988-10-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-10-28 | 1992-04-28 | 1992-10-28 | $7700.00 | Window Closed / Lapsed |